Symbols / OABI Stock $2.01 +8.65% OmniAb, Inc.

Healthcare • Biotechnology • United States • NGM
OABI (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Mr. Matthew W. Foehr
Exch · Country NGM · United States
Market Cap 291.39M
Enterprise Value 261.99M
Income -54.29M
Sales 28.94M
FCF (ttm) -2.57M
Book/sh 1.81
Cash/sh 0.34
Employees 89
Insider 10d —
IPO Sep 30, 2021
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -6.23
PEG —
P/S 10.07
P/B 1.11
P/C —
EV/EBITDA -7.84
EV/Sales 9.05
Quick Ratio 4.55
Current Ratio 4.80
Debt/Eq 7.49
LT Debt/Eq —
EPS (ttm) -0.46
EPS next Y -0.32
EPS Growth —
Revenue Growth 247.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-08-06
Earnings (prior) 2026-05-07
ROA -11.32%
ROE -20.25%
ROIC —
Gross Margin 98.91%
Oper. Margin -54.27%
Profit Margin -187.59%
Shs Outstand 144.97M
Shs Float 97.53M
Insider Own 15.24%
Instit Own 51.53%
Short Float 3.98%
Short Ratio 9.51
Short Interest 5.26M
52W High 2.29
vs 52W High -12.42%
52W Low 1.22
vs 52W Low 64.75%
Beta 0.62
Impl. Vol. 25.00%
Rel Volume 2.36
Avg Volume 529.04K
Volume 1.25M
Target (mean) $7.33
Tgt Median $8.00
Tgt Low $3.00
Tgt High $11.00
# Analysts 6
Recom Strong_buy
Prev Close $1.85
Price $2.01
Change 8.65%
About

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan, China, and Canada. The company's technology platform creates and screens diverse antibody repertoires to identify optimal antibodies and other target-binding proteins for partners' drug development efforts. Its OmniAb platform's Biological Intelligence powers the immune systems of its proprietary and engineered transgenic animals to create optimized antibody candidates for human therapeutics. The company offers animal-based technologies include OmniRat, OmniChicken, and OmniMouse, which have been genetically modified to generate antibodies with human sequences; OmniFlic, a bispecific rat and OmniClic, a bispecific chicken are designed for discovery of bispecific antibody applications; OmniTaur, which provides cow-inspired antibodies with unique structural characteristics for challenging targets; OmnidAb, an in vivo platform for the discovery of single-domain antibodies based upon a human VH scaffold; and OmniDeep, a suite of in silico, an artificial intelligence (AI) and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. It has an agreement with mAbsolve Ltd. for its Fc-silencing platform technology to incorporate the STR technology into antibodies that have been generated using OmniAb's antibody discovery platform. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$7.33
Mean price target
2. Current target
$2.11
Latest analyst target
3. DCF / Fair value
$-0.32
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.11
Low
$3.00
High
$11.00
Mean
$7.33

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2025-08-07 main RBC Capital Outperform → Outperform $3
2025-05-12 reit Benchmark Buy → Buy $6
2025-03-27 main RBC Capital Outperform → Outperform $4
2025-03-20 main Benchmark Buy → Buy $6
2025-03-19 reit HC Wainwright & Co. Buy → Buy $11
2024-11-14 reit Benchmark Buy → Buy $8
2024-11-14 reit HC Wainwright & Co. Buy → Buy $11
2024-08-19 reit Benchmark Buy → Buy $8
2024-08-16 reit RBC Capital Outperform → Outperform $7
2024-08-12 reit HC Wainwright & Co. Buy → Buy $11
2024-05-14 reit Benchmark Buy → Buy $8
2024-03-26 main Truist Securities Buy → Buy $10
2024-03-22 reit Benchmark Buy → Buy $8
2024-03-21 reit HC Wainwright & Co. Buy → Buy $11
2024-03-21 reit RBC Capital Outperform → Outperform $7
2023-11-14 reit Benchmark Buy → Buy $8
2023-08-11 reit HC Wainwright & Co. Buy → Buy $11
2023-05-12 reit Benchmark Buy → Buy $8
2023-04-21 init Benchmark — → Buy $8
2023-04-13 init Craig-Hallum — → Buy $10
News
RSS: Latest OABI news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-21 GOTWALS PHILIP J Director — 13,333 — —
2026-04-21 CROUSE STEVEN C. Director — 13,333 — —
2026-04-07 FOEHR MATTHEW W Chief Executive Officer — 19,244 $1.49 $28,674
2026-04-07 BERKMAN CHARLES S Officer — 7,157 $1.49 $10,664
2026-04-07 GUSTAFSON KURT A Chief Financial Officer — 6,913 $1.49 $10,300
2026-04-07 FOEHR MATTHEW W Chief Executive Officer — 36,459 — —
2026-04-07 BERKMAN CHARLES S Officer — 13,542 — —
2026-04-07 GUSTAFSON KURT A Chief Financial Officer — 13,542 — —
2026-02-18 FOEHR MATTHEW W Chief Executive Officer — 30,843 $1.71 $52,742
2026-02-18 BERKMAN CHARLES S Officer — 9,673 $1.71 $16,541
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
18.67
-29.27%
26.39
-22.75%
34.16
-42.17%
59.08
Operating Revenue
18.67
-29.27%
26.39
-22.75%
34.16
-42.17%
59.08
Cost Of Revenue
0.30
0.00
—
—
Reconciled Cost Of Revenue
0.30
0.00
—
—
Gross Profit
18.36
-30.42%
26.39
—
—
Operating Expense
87.33
-13.44%
100.89
-2.60%
103.58
+20.83%
85.72
Research And Development
47.75
-13.35%
55.11
-2.50%
56.52
+16.87%
48.36
Selling General And Administration
29.21
-4.96%
30.74
-7.72%
33.31
+33.77%
24.90
General And Administrative Expense
29.21
-4.96%
30.74
-7.72%
33.31
+33.77%
24.90
Other Gand A
29.21
-4.96%
30.74
-7.72%
33.31
+33.77%
24.90
Other Operating Expenses
-2.55
-7.78%
-2.37
-1338.22%
0.19
+132.26%
-0.59
Total Expenses
87.64
-13.14%
100.89
-2.60%
103.58
+20.83%
85.72
Operating Income
-68.97
+7.43%
-74.50
-7.32%
-69.42
-160.50%
-26.65
Total Operating Income As Reported
-68.97
+7.43%
-74.50
-7.32%
-69.42
-160.50%
-26.65
EBITDA
-47.22
+7.27%
-50.92
-2.00%
-49.92
-494.38%
-8.40
Normalized EBITDA
-47.22
+7.27%
-50.92
-2.00%
-49.92
-494.38%
-8.40
Reconciled Depreciation
21.75
-7.76%
23.58
+20.96%
19.50
+6.84%
18.25
EBIT
-68.97
+7.43%
-74.50
-7.32%
-69.42
-160.50%
-26.65
Net Income
-64.78
-4.43%
-62.03
-22.55%
-50.62
-126.65%
-22.33
Pretax Income
-66.29
+7.17%
-71.41
-10.95%
-64.36
-146.97%
-26.06
Net Non Operating Interest Income Expense
2.66
-14.36%
3.11
-38.56%
5.05
+761.16%
0.59
Interest Expense Non Operating
—
—
—
0.00
Net Interest Income
2.66
-14.36%
3.11
-38.56%
5.05
+761.16%
0.59
Interest Expense
—
—
—
0.00
Interest Income Non Operating
2.66
-14.36%
3.11
-38.56%
5.05
+761.16%
0.59
Interest Income
2.66
-14.36%
3.11
-38.56%
5.05
+761.16%
0.59
Other Income Expense
0.01
+200.00%
-0.01
-1600.00%
0.00
—
Other Non Operating Income Expenses
0.01
+200.00%
-0.01
-1600.00%
0.00
—
Tax Provision
-1.51
+83.85%
-9.38
+31.77%
-13.74
-268.77%
-3.73
Tax Rate For Calcs
0.00
-82.44%
0.00
-38.79%
0.00
+49.65%
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-64.78
-4.43%
-62.03
-22.55%
-50.62
-126.65%
-22.33
Net Income From Continuing Operation Net Minority Interest
-64.78
-4.43%
-62.03
-22.55%
-50.62
-126.65%
-22.33
Net Income From Continuing And Discontinued Operation
-64.78
-4.43%
-62.03
-22.55%
-50.62
-126.65%
-22.33
Net Income Continuous Operations
-64.78
-4.43%
-62.03
-22.55%
-50.62
-126.65%
-22.33
Normalized Income
-64.78
-4.43%
-62.03
-22.55%
-50.62
-126.65%
-22.33
Net Income Common Stockholders
-64.78
-4.43%
-62.03
-22.55%
-50.62
-126.65%
-22.33
Diluted EPS
-0.57
+6.56%
-0.61
-19.61%
-0.51
-96.15%
-0.26
Basic EPS
-0.57
+6.56%
-0.61
-19.61%
-0.51
-96.15%
-0.26
Basic Average Shares
113.64
+11.01%
102.36
+2.69%
99.68
+16.84%
85.32
Diluted Average Shares
113.64
+11.01%
102.36
+2.69%
99.68
+16.84%
85.32
Diluted NI Availto Com Stockholders
-64.78
-4.43%
-62.03
-22.55%
-50.62
-126.65%
-22.33
Amortization
12.91
-25.82%
17.41
+28.43%
13.55
+3.86%
13.05
Amortization Of Intangibles Income Statement
12.91
-25.82%
17.41
+28.43%
13.55
+3.86%
13.05
Depreciation Amortization Depletion Income Statement
12.91
-25.82%
17.41
+28.43%
13.55
+3.86%
13.05
Depreciation And Amortization In Income Statement
12.91
-25.82%
17.41
+28.43%
13.55
+3.86%
13.05
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Assets
300.91
-7.57%
325.56
-13.24%
375.23
-10.92%
421.21
Current Assets
65.34
-4.10%
68.14
-28.20%
94.90
-24.05%
124.95
Cash Cash Equivalents And Short Term Investments
54.02
-9.10%
59.43
-31.67%
86.98
-1.45%
88.27
Cash And Cash Equivalents
25.52
-7.52%
27.60
+68.71%
16.36
-51.01%
33.39
Cash Financial
—
—
—
33.39
Other Short Term Investments
28.50
-10.48%
31.84
-54.92%
70.62
+28.70%
54.88
Receivables
7.39
+40.17%
5.27
+37.15%
3.84
-87.31%
30.29
Accounts Receivable
7.39
+40.17%
5.27
+37.15%
3.84
-87.31%
30.29
Gross Accounts Receivable
—
—
—
—
Allowance For Doubtful Accounts Receivable
—
—
—
—
Other Current Assets
3.93
+14.39%
3.43
-15.76%
4.07
-36.29%
6.39
Total Non Current Assets
235.57
-8.49%
257.42
-8.17%
280.32
-5.38%
296.26
Net PPE
24.97
-24.96%
33.28
-12.72%
38.13
-8.03%
41.46
Gross PPE
44.30
-4.06%
46.18
-1.76%
47.01
+0.77%
46.65
Accumulated Depreciation
-19.33
-49.85%
-12.90
-45.35%
-8.88
-71.09%
-5.19
Properties
0.00
0.00
0.00
0.00
Machinery Furniture Equipment
10.97
+4.02%
10.54
+3.32%
10.21
+16.41%
8.77
Construction In Progress
0.05
-55.34%
0.10
-87.77%
0.84
+167.30%
0.32
Other Properties
15.54
-12.61%
17.79
-10.54%
19.88
-7.44%
21.48
Leases
17.75
+0.00%
17.75
+10.38%
16.08
-0.05%
16.09
Goodwill And Other Intangible Assets
209.13
-5.81%
222.04
-7.27%
239.45
-4.69%
251.22
Goodwill
83.98
+0.00%
83.98
+0.00%
83.98
+0.00%
83.98
Other Intangible Assets
125.15
-9.35%
138.06
-11.20%
155.47
-7.04%
167.24
Other Non Current Assets
1.47
-29.90%
2.10
-23.50%
2.75
-23.30%
3.58
Total Liabilities Net Minority Interest
33.89
-10.68%
37.94
-37.43%
60.64
-24.05%
79.84
Current Liabilities
16.25
+7.73%
15.09
-34.73%
23.12
-11.17%
26.02
Payables And Accrued Expenses
2.21
-20.12%
2.76
-55.53%
6.21
-20.92%
7.86
Payables
1.88
-18.20%
2.30
-59.31%
5.64
-12.56%
6.46
Accounts Payable
1.88
-18.20%
2.30
-47.93%
4.41
+48.47%
2.97
Other Payable
—
—
1.23
—
Current Accrued Expenses
0.33
-29.55%
0.47
-18.07%
0.57
-59.37%
1.40
Pensionand Other Post Retirement Benefit Plans Current
5.79
+5.85%
5.47
+4.21%
5.25
+27.94%
4.10
Total Tax Payable
—
—
0.00
-100.00%
3.48
Income Tax Payable
—
—
0.00
-100.00%
3.48
Current Debt And Capital Lease Obligation
3.88
+2.56%
3.78
+8.49%
3.49
+95.84%
1.78
Current Capital Lease Obligation
3.88
+2.56%
3.78
+8.49%
3.49
+95.84%
1.78
Current Deferred Liabilities
3.16
+35.26%
2.34
-65.87%
6.85
-16.56%
8.21
Current Deferred Revenue
3.16
+35.26%
2.34
-65.87%
6.85
-16.56%
8.21
Other Current Liabilities
1.22
+65.26%
0.74
-44.17%
1.32
-67.61%
4.08
Total Non Current Liabilities Net Minority Interest
17.63
-22.84%
22.85
-39.10%
37.52
-30.27%
53.82
Long Term Debt And Capital Lease Obligation
16.45
-15.10%
19.38
-12.20%
22.07
-8.08%
24.02
Long Term Capital Lease Obligation
16.45
-15.10%
19.38
-12.20%
22.07
-8.08%
24.02
Non Current Deferred Liabilities
0.79
-67.71%
2.43
-80.10%
12.22
-52.40%
25.67
Non Current Deferred Revenue
0.00
-100.00%
0.12
-86.43%
0.86
-80.07%
4.33
Non Current Deferred Taxes Liabilities
0.79
-66.08%
2.31
-79.62%
11.35
-46.80%
21.34
Other Non Current Liabilities
0.39
-62.18%
1.04
-67.86%
3.23
-21.81%
4.13
Stockholders Equity
267.03
-7.16%
287.62
-8.57%
314.58
-7.85%
341.37
Common Stock Equity
267.03
-7.16%
287.62
-8.57%
314.58
-7.85%
341.37
Capital Stock
0.01
+16.67%
0.01
+0.00%
0.01
+0.00%
0.01
Common Stock
0.01
+16.67%
0.01
+0.00%
0.01
+0.00%
0.01
Preferred Stock
0.00
0.00
0.00
0.00
Share Issued
144.31
+18.68%
121.60
+4.06%
116.86
+1.42%
115.22
Ordinary Shares Number
144.31
+18.68%
121.60
+4.06%
116.86
+1.42%
115.22
Additional Paid In Capital
433.18
+11.36%
388.98
+9.92%
353.89
+7.21%
330.10
Retained Earnings
-166.18
-63.88%
-101.40
-157.58%
-39.37
-449.87%
11.25
Gains Losses Not Affecting Retained Earnings
0.01
-55.56%
0.03
-46.00%
0.05
+455.56%
0.01
Other Equity Adjustments
0.01
-55.56%
0.03
-46.00%
0.05
+455.56%
0.01
Total Equity Gross Minority Interest
267.03
-7.16%
287.62
-8.57%
314.58
-7.85%
341.37
Total Capitalization
267.03
-7.16%
287.62
-8.57%
314.58
-7.85%
341.37
Working Capital
49.09
-7.47%
53.05
-26.10%
71.78
-27.44%
98.93
Invested Capital
267.03
-7.16%
287.62
-8.57%
314.58
-7.85%
341.37
Total Debt
20.33
-12.22%
23.16
-9.38%
25.56
-0.91%
25.80
Capital Lease Obligations
20.33
-12.22%
23.16
-9.38%
25.56
-0.91%
25.80
Net Tangible Assets
57.90
-11.71%
65.58
-12.72%
75.14
-16.65%
90.15
Tangible Book Value
57.90
-11.71%
65.58
-12.72%
75.14
-16.65%
90.15
Dueto Related Parties Current
—
—
1.23
0.00
Other Equity Interest
—
—
—
—
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-36.45
+8.09%
-39.66
-1789.99%
2.35
+165.43%
-3.59
Cash Flow From Continuing Operating Activities
-36.45
+8.09%
-39.66
-1789.99%
2.35
+165.43%
-3.59
Net Income From Continuing Operations
-64.78
-4.43%
-62.03
-22.55%
-50.62
-126.65%
-22.33
Depreciation Amortization Depletion
21.75
-7.76%
23.58
+20.96%
19.50
+6.84%
18.25
Depreciation And Amortization
21.75
-7.76%
23.58
+20.96%
19.50
+6.84%
18.25
Other Non Cash Items
1.09
+154.22%
-2.00
-731.12%
-0.24
+40.05%
-0.40
Stock Based Compensation
15.82
-26.40%
21.50
-13.38%
24.82
+35.47%
18.32
Deferred Tax
-1.53
+83.09%
-9.04
+27.91%
-12.54
-95.36%
-6.42
Deferred Income Tax
-1.53
+83.09%
-9.04
+27.91%
-12.54
-95.36%
-6.42
Operating Gains Losses
-3.00
—
—
—
Gain Loss On Investment Securities
—
—
—
—
Gain Loss On Sale Of PPE
-3.00
0.00
—
—
Change In Working Capital
-4.95
+51.31%
-10.17
-140.90%
24.87
+329.59%
-10.83
Change In Receivables
0.19
+130.24%
-0.62
-102.32%
26.90
+311.18%
-12.74
Changes In Account Receivables
0.19
+130.24%
-0.62
-102.32%
26.90
+311.18%
-12.74
Change In Prepaid Assets
-1.11
-272.74%
0.64
-72.34%
2.32
+149.24%
-4.71
Change In Payables And Accrued Expense
-0.23
+90.41%
-2.41
-361.96%
0.92
-93.89%
15.07
Change In Payable
-0.23
+90.41%
-2.41
-361.96%
0.92
-93.89%
15.07
Change In Account Payable
-0.23
+90.41%
-2.41
-361.96%
0.92
-93.89%
15.07
Change In Other Working Capital
-1.60
+73.28%
-5.99
-11.99%
-5.35
+43.65%
-9.49
Change In Other Current Assets
0.63
-2.64%
0.65
+0.47%
0.64
+181.47%
-0.79
Change In Other Current Liabilities
-2.83
-16.17%
-2.44
-332.68%
-0.56
-130.82%
1.83
Investing Cash Flow
6.47
-82.93%
37.88
+306.16%
-18.38
+74.93%
-73.31
Cash Flow From Continuing Investing Activities
6.47
-82.93%
37.88
+306.16%
-18.38
+74.93%
-73.31
Net PPE Purchase And Sale
-0.56
+69.87%
-1.88
-14.05%
-1.64
+90.42%
-17.17
Purchase Of PPE
-0.56
+69.87%
-1.88
-14.05%
-1.64
+90.42%
-17.17
Capital Expenditure
-0.56
+69.87%
-1.88
-14.05%
-1.64
+90.42%
-17.17
Net Investment Purchase And Sale
4.03
-89.96%
40.16
+426.71%
-12.29
+77.53%
-54.70
Purchase Of Investment
-46.86
-16.31%
-40.29
+64.23%
-112.62
-105.60%
-54.77
Sale Of Investment
50.89
-36.74%
80.45
-19.81%
100.32
+143220.00%
0.07
Net Business Purchase And Sale
—
—
—
—
Purchase Of Business
—
—
—
—
Net Intangibles Purchase And Sale
—
—
—
—
Net Other Investing Changes
3.00
+850.00%
-0.40
+90.99%
-4.44
-208.33%
-1.44
Financing Cash Flow
27.91
+114.39%
13.02
+1559.64%
-0.89
-100.81%
110.74
Cash Flow From Continuing Financing Activities
27.91
+114.39%
13.02
+1559.64%
-0.89
-100.81%
110.74
Net Common Stock Issuance
28.20
+148.03%
11.37
0.00
-100.00%
96.24
Proceeds From Stock Option Exercised
0.49
-84.99%
3.26
+170.29%
1.21
+93.11%
0.62
Net Other Financing Charges
-0.77
+51.81%
-1.61
+23.41%
-2.10
-115.12%
13.87
Changes In Cash
-2.07
-118.45%
11.24
+166.43%
-16.92
-150.00%
33.84
Beginning Cash Position
28.16
+66.44%
16.92
-50.00%
33.84
0.00
End Cash Position
26.08
-7.37%
28.16
+66.44%
16.92
-50.00%
33.84
Free Cash Flow
-37.02
+10.88%
-41.54
-6008.82%
0.70
+103.39%
-20.75
Income Tax Paid Supplemental Data
—
0.02
-99.39%
2.61
0.00
Amortization Of Securities
-0.86
+42.72%
-1.50
+56.47%
-3.44
-1924.12%
-0.17
Common Stock Issuance
28.20
+148.03%
11.37
0.00
-100.00%
96.24
Issuance Of Capital Stock
28.20
+148.03%
11.37
0.00
-100.00%
96.24
Sale Of Intangibles
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category